Legal & General Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-43,044
| Closed | -$2.53M | – | 3402 |
|
|
2023
Q4 | $2.53M | Sell |
43,044
-3,941
| -8% | -$222K | ﹤0.01% | 1828 |
|
|
2023
Q3 | $2.05M | Buy |
46,985
+7,994
| +21% | +$285K | ﹤0.01% | 1894 |
|
|
2023
Q2 | $1.41M | Sell |
38,991
-1,244
| -3% | -$51.3K | ﹤0.01% | 2077 |
|
|
2023
Q1 | $1.5M | Buy |
40,235
+5,076
| +14% | +$228K | ﹤0.01% | 2008 |
|
|
2022
Q4 | $1.59M | Sell |
35,159
-1,096
| -3% | -$70.9K | ﹤0.01% | 1976 |
|
|
2022
Q3 | $2.53M | Sell |
36,255
-2,142
| -6% | -$158K | ﹤0.01% | 1742 |
|
|
2022
Q2 | $2.58M | Sell |
38,397
-294
| -0.8% | -$18.7K | ﹤0.01% | 1752 |
|
|
2022
Q1 | $3.18M | Buy |
38,691
+2,353
| +6% | +$241K | ﹤0.01% | 1775 |
|
|
2021
Q4 | $5.33M | Sell |
36,338
-1,063
| -3% | -$165K | ﹤0.01% | 1535 |
|
|
2021
Q3 | $6.62M | Buy |
37,401
+8,306
| +29% | +$1.34M | ﹤0.01% | 1394 |
|
|
2021
Q2 | $4.7M | Buy |
29,095
+1,608
| +6% | +$258K | ﹤0.01% | 1564 |
|
|
2021
Q1 | $4.71M | Sell |
27,487
-514
| -2% | -$102K | ﹤0.01% | 1583 |
|
|
2020
Q4 | $6.15M | Buy |
28,001
+5,278
| +23% | +$1.14M | ﹤0.01% | 1364 |
|
|
2020
Q3 | $3.77M | Sell |
22,723
-5
| -0% | -$684 | ﹤0.01% | 1486 |
|
|
2020
Q2 | $2.6M | Buy |
22,728
+1,278
| +6% | +$124K | ﹤0.01% | 1620 |
|
|
2020
Q1 | $1.65M | Buy |
21,450
+3,920
| +22% | +$352K | ﹤0.01% | 1664 |
|
|
2019
Q4 | $2.26M | Buy |
17,530
+1,067
| +6% | +$103K | ﹤0.01% | 1744 |
|
|
2019
Q3 | $1.28M | Buy |
16,463
+11,370
| +223% | +$1.07M | ﹤0.01% | 1894 |
|
|
2019
Q2 | $525K | Buy |
5,093
+1,004
| +25% | +$78.2K | ﹤0.01% | 2134 |
|
|
2019
Q1 | $299K | Buy |
4,089
+454
| +12% | +$30.9K | ﹤0.01% | 2251 |
|
|
2018
Q4 | $154K | Buy |
3,635
+515
| +17% | +$20.5K | ﹤0.01% | 2362 |
|
|
2018
Q3 | $147K | Buy |
3,120
+78
| +3% | +$4.34K | ﹤0.01% | 2401 |
|
|
2018
Q2 | $150K | Buy |
+3,042
| New | +$115K | ﹤0.01% | 2365 |
|
|
2017
Q2 | – | Sell |
-3,790
| Closed | -$19K | – | 3395 |
|
|
2017
Q1 | $19K | Hold |
3,790
| – | – | ﹤0.01% | 3094 |
|
|
2016
Q4 | $18K | Buy |
3,790
+1,560
| +70% | +$8.49K | ﹤0.01% | 3138 |
|
|
2016
Q3 | $15K | Hold |
2,230
| – | – | ﹤0.01% | 2834 |
|
|
2016
Q2 | $12K | Hold |
2,230
| – | – | ﹤0.01% | 2881 |
|
|
2016
Q1 | $48K | Hold |
2,230
| – | – | ﹤0.01% | 2433 |
|
|
2015
Q4 | $69K | Buy |
+2,230
| New | +$78.8K | ﹤0.01% | 2286 |
|
Other funds holding MRTX
Legal & General Group's MRTX Position: Q1 2024 in Review
Legal & General Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 43,044 shares — an estimated $2.53M sold.
Legal & General Group first reported a position in MRTX in Q4 2015 and held it in 29 quarters. The position peaked at $6.62M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Legal & General Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Legal & General Group sold 43,044 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.53M.
- Legal & General Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 29 quarters.
- Legal & General Group's Mirati Therapeutics, Inc. Common Stock position peaked at $6.62M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Legal & General Group's 13F filing for Q1 2024, filed 14 May 2024.